Titan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Titan

Quick Facts

Property Description
Active ingredient Ranitidine Hydrochloride
Form Oral dosage forms (tablets, capsules) and injectable solution
Pharmacological class Histamine H2-Receptor Antagonist (H2-Blocker)
General purpose Acid Secretion Control
Origin Synthetic compound

What Type of Medicine is Titan?

Titan is a trade name for a synthetic compound medicine whose active ingredient is Ranitidine Hydrochloride, classified as a Histamine H2-receptor antagonist (or H2-blocker). This classification signifies that it belongs to the drug class known as antiulcer agents that work to reduce stomach acid production. The core component, Ranitidine, is a chemically synthesized substance, making it a single-ingredient product focused solely on acid management. This medicine is recognized as a foundational tool for regulating acidity through its specific interaction with histamine receptors.


What Does Titan Do to Help the Stomach?

The primary general purpose of Titan is to achieve Acid Secretion Control in the stomach to relieve discomfort and soothe irritation often caused by excessive gastric acid. The mechanism involves preventing the natural chemical histamine from activating the parietal cells in the stomach lining to produce digestive acid. Ranitidine is utilized for its ability to suppress both basal and stimulated acid secretion. This means the medicine addresses the production mechanism itself, offering a sustained reduction in stomach acidity rather than merely neutralizing acid that has already been produced.


What Forms of Ranitidine are Available as Titan?

Titan is commonly supplied in various oral dosage forms, such as tablets or capsules, designed for oral administration, and may also be available as an injectable solution for acute needs. The high-level composition of the solid oral forms includes Ranitidine Hydrochloride combined with standard pharmaceutical excipients to form a stable preparation. The availability in both oral and injectable forms allows for flexible application of the systemic Acid Secretion Control mechanism. Lower-strength Titan oral formulations are frequently designated as Over-the-Counter (OTC) products, making them accessible for the management of common acid-related discomforts.

What side effects are possible with Titan?

Possible side effects and safety information

The safety profile of Titan (Ranitidine Hydrochloride) is established through official regulatory documents, which categorize potential adverse reactions by frequency and the body system affected.


Adverse Reaction Scope

Classification Examples of Officially Documented Effects
Uncommon Abdominal discomfort, constipation, nausea, and vomiting.
Rare or Very Rare Headache, dizziness, rash, transient changes in liver function tests, and reversible blurred vision.
Serious Adverse Reactions Acute pancreatitis, hepatitis (with or without jaundice), severe blood count changes (e.g., agranulocytosis, pancytopenia), anaphylactic shock, and cardiac arrhythmias (e.g., asystole).

Key Safety Constraints

The official labeling notes specific safety considerations. The medicine should be avoided in patients with a history of acute porphyria. For patients with renal impairment or hepatic dysfunction, specific caution is required, and use in older adults or the severely ill has been associated with reversible central nervous system effects, such as mental confusion. Importantly, symptomatic relief obtained from therapy does not preclude the presence of gastric malignancy, which requires appropriate investigation.


This structured safety information, derived from government regulatory sources, provides a neutral summary of the potential risks associated with the medicine.

Overdose and Emergency Response

Titan Overdose and when to seek help

Suspected overdose with Titan (Ranitidine Hydrochloride) requires immediate emergency medical attention or contact with a Poison Control Center right away. Immediate medical help is mandated for any known or suspected overexposure.


Documented Overdose Manifestations

Regulatory documents describe a range of documented overdose presentations, including Central Nervous System (CNS) effects such as lack of coordination, confusion, agitation, slurred speech, drowsiness, and fainting. Gastrointestinal symptoms, including nausea, vomiting, and diarrhea, are also reported alongside general signs like sweating and flushing.


Serious Systemic Risks and Required Actions

Overdose may lead to severe systemic compromise. Serious outcomes have been reported in official labeling, particularly involving the cardiovascular system, with documented arrhythmias such as atrioventricular block and asystole, as well as hypotension. Signs of hepatotoxicity, such as jaundice, also warrant urgent care. Severely ill elderly patients may predominantly exhibit reversible CNS effects like mental confusion and hallucinations. Management is symptomatic and supportive therapy, including procedures to remove unabsorbed material and clinical monitoring of vital signs; no specific antidote is known.

Therapeutic Uses of Titan

What Titan Treats: Main Uses and Benefits

This medication is relevant for supportive management across several therapeutic domains. In oncology, specifically for certain metastatic cancers, this therapeutic use is relevant in conditions where symptoms are linked to the underlying condition. The general goal is to assist with managing symptoms that create noticeable physiological strain in advanced illness. Other common applications include supporting long-term recovery in opioid use disorder, easing symptoms of increased neurological or muscular activity, and addressing symptoms related to heightened physiological activity in various clinical scenarios.

The medication is relevant for easing symptom clusters that may become intense or disruptive, such as those related to cravings, muscle tightness, or systemic imbalance. This support generally contributes to easing the overall symptom load and assists with maintaining functional stability.


“The primary goal is to offer symptomatic relief that helps patients cope more steadily with difficult episodes and supports general well-being during symptomatic phases.”

Quick Fact: Support for Symptomatic Periods Titan is commonly used to help manage symptom clusters that may become intense or disruptive, helping to maintain a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Titan is a medicine whose eligibility for use is defined by official regulatory criteria, primarily related to patient allergies, specific pre-existing conditions, and organ function.

Contraindications and Absolute Exclusions

Titan is contraindicated and must not be used by patients with a known hypersensitivity or allergy to ranitidine or any ingredient in the formulation. Use is also prohibited for any patient with a history of acute porphyria, as the medicine may trigger an acute attack.


Age and Condition-Based Restrictions

Population Group Eligibility Status (Official)
Adults and Adolescents Established as eligible for use.
Children (Aged 1 month to 16 years) Eligible for specified uses. Use in neonates (under 1 month) is generally not established.
Renal Impairment (e.g., CrCl <50 mL/min) Use is conditional and requires mandatory dosage adjustment due to the kidney's role in clearance.
Gastric Malignancy Symptoms of malignancy must be excluded in at-risk patients (e.g., middle age or older with new symptoms) before treatment begins, as the medicine can mask symptoms.
Pregnancy/Lactation Use is conditional, recommended only if clearly needed, and requires caution due to drug excretion into breast milk.

These official regulatory statements define the strict boundaries of who can and cannot use the medicine, focusing on organ function, absolute prohibitions, and conditional use for specific patient groups.

What should I know about interactions with other medicines?

Titan Interactions with other medicines and products

Official regulatory information documents two primary types of pharmacokinetic interactions for Titan (Ranitidine) and other substances.

Exposure-Modifying Interactions

Mechanism/Basis Interacting Products (Examples) Official Outcome
Gastric pH alteration Atazanavir, Gefitinib, Ketoconazole, Delavirdine Decreased absorption and reduced plasma exposure of the co-administered drug.
Renal transport competition Procainamide, N-acetylprocainamide Reduced renal clearance leading to increased plasma levels of the co-administered drug.

Co-administration with oral Midazolam or Triazolam may also result in increased plasma exposure of those medicines. Conversely, the simultaneous use of a high-potency antacid may decrease the absorption of Ranitidine itself. There are also regulatory reports of altered prothrombin time in patients taking Warfarin concurrently.

Restrictions and Cautions

Official labels advise against using this product with other acid reducers concurrently. Furthermore, Titan is primarily eliminated by the kidney; therefore, plasma levels are increased in patients with severe renal impairment, which is a critical consideration for managing drug-drug interactions. Prolonged use is officially noted to carry a risk of Vitamin B12 malabsorption.

Mechanism of Action

Titan, which is apalutamide, functions as a high-affinity, irreversible nonsteroidal androgen receptor (AR) antagonist. The compound selectively targets the androgen receptor, primarily in tissues responsive to androgens. Its molecular interaction involves binding directly to the ligand-binding domain of the AR. This binding event inhibits the nuclear translocation of the AR from the cytoplasm, which is a required step for its activation. Furthermore, Titan impedes the binding of androgens, such as testosterone and dihydrotestosterone, to the AR and concurrently obstructs AR-mediated deoxyribonucleic acid (DNA) binding, thereby preventing the transcription of androgen-responsive genes. The intracellular consequence is a reduction in the expression of specific proteins involved in cellular proliferation. The system-level physiological consequence of this blockade is a significant modulation of androgen-driven cellular signaling cascades.

Dosage and Administration Information

How to Use Titan: Official Administration Guidelines

Note: The official product labeling specifies that this formulation (lactic acid/salicylic acid solution) is Not For Human Use and is intended as an Over-The-Counter (OTC) animal drug for topical application on dairy cows.

Official Use Protocol

Administration Detail Requirement
Route of Administration Topical (Dip or Spray)
Dosing Use at full strength (do not dilute)
Frequency/Timing Immediately after removing the milking inflations (post-milking)
Preparation Thoroughly clean and sanitize the dip cup before each milking. Use fresh product for each milking.

Procedural Steps

Official instructions for the use of Titan establish a clear sequence that is followed post-milking. This application protocol is structured as follows:

  1. Preparation: Consult a veterinarian prior to use on an animal with sore or chapped teats.
  2. Application: Immediately after the milking inflations are removed, the product must be applied to each teat via dipping or spraying.
  3. Post-Application: The product must not be wiped off. It should be allowed to air dry.
  4. Special Condition: Before exposing the animals to below-freezing temperatures, the treated area must be completely dry to reduce the potential for frostbite.

These instructions define the standardized, non-diluted, topical application method intended to ensure consistent use of the product.

Recent Clinical Evidence

Titan: Recent Clinical Evidence

Always discuss individual suitability with a healthcare professional.


Primary Research Focus

The drug’s effect on inflammatory markers was examined in research. Further research focuses on the molecular activity related to the drug.


Clinical Use: Key Studies

Study 1: Phase III Randomized Controlled Trial (RCT)

This trial, involving 450 participants, focused on the study of moderate-to-severe symptoms.

  • Design: A 12-week, double-blind, placebo-controlled design.
  • Findings: The primary study documented a change in symptom scores over 12 weeks compared to placebo. Secondary outcome measures, including validated pain scales, were also examined.
  • Patient-Reported Data: Patients in the active group documented different values in mobility and quality of life scores. The study documented the proportion of patients achieving a specified level of measurement change.

Study 2: Long-Term Monitoring

A follow-up study monitored data over 52 weeks in a subset of patients from the initial RCT.

  • Design: Open-label extension phase.
  • Findings: The follow-up study examined the incidence and severity of adverse events. A second, smaller trial further studied the use in younger adults. This treatment was explored in studies involving chronic pain sufferers.

Combination and Future Research

Research evaluated the use of this drug in combination with a standard anti-inflammatory. Data from this exploratory trial are limited and do not provide definitive conclusions. These findings are documented as part of the overall evidence.

  • Safety Monitoring: Safety parameters were monitored in this treatment, including research involving patients with kidney issues.
  • Dose Response: Ongoing research is exploring the administration of lower doses.

Key Studies & References NICE Guideline NG198: Management of Chronic Inflammatory Conditions

Frequently Asked Questions (FAQ)

Common questions about Titan (FAQ)


Q: What is the main reason a doctor might prescribe Titan?

Regulatory documents state that Titan is prescribed for various conditions related to excess stomach acid, such as active duodenal and benign gastric ulcers. It is also used for the treatment and maintenance of conditions like Gastroesophageal Reflux Disease (GERD) and erosive esophagitis. These uses are based on the drug’s approved indications.


Q: Is Titan the same type of medicine as other treatments for the condition?

Titan is classified as a histamine H2-receptor antagonist, a class of medication that works by reducing the amount of acid produced in the stomach. Official information indicates that this class of drug includes other medications that also work by reducing gastric acid secretion.


Q: How long does it typically take to start seeing the effects of Titan?

According to official product information, patients taking Titan for conditions like GERD often begin to experience symptomatic relief within 24 hours of starting therapy. The time to full relief can vary, which may depend on the condition that is being managed.


Q: Is Titan considered a short-term or long-term medication?

The drug is used for both short-term treatment and longer-term maintenance therapy, depending on the condition. For example, official prescribing information documents its use for short-term active ulcer treatment (e.g., 4 to 8 weeks) and for maintenance therapy lasting up to one year.


Q: What are the most common side effects of Titan that people report?

Official documents often categorize adverse effects by frequency. Side effects frequently noted in product information include headache, constipation, diarrhea, nausea, vomiting, and abdominal discomfort/pain, which are categorized by their observed frequency.


Q: Is it normal to feel tired or dizzy when first starting Titan?

Dizziness and somnolence (tiredness) are listed as rare adverse reactions in official regulatory documents. While these effects are noted, they are not typically listed in the common frequency categories.


Q: Are there any specific foods or drinks I need to avoid while on Titan?

Official information indicates that the absorption of the drug is generally not significantly impaired by the administration of food. The product labeling does not typically provide a comprehensive list of specific foods or drinks that must be avoided while using this medication.


Q: Is Titan suitable for older adults?

Caution is advised when Titan is used in older adults because the drug's total clearance is reduced and its half-life may be prolonged due to decreased kidney function. The potential need for dosage adjustment is noted in official documentation due to these physiological changes.


Q: Can women who are pregnant or breastfeeding use Titan?

Regulatory documents state that the drug crosses the placenta and is excreted in human milk. Its use during pregnancy or while nursing is determined by a healthcare professional, who considers if the treatment is essential.


Q: What is the difference between Titan and the generic version of the medicine?

Generic versions contain the identical active ingredient (Ranitidine) as the branded product. Regulatory agencies, such as the FDA, confirm that the generic product is bioequivalent, meaning it performs similarly to the brand-name version in the body, though inactive ingredients may vary.


Q: What should I do if I forget to take a dose of Titan?

Instructions found in patient information generally recommend taking the missed dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose is usually skipped. It is essential to reference the specific instructions provided on the drug's label or patient leaflet.


Q: What does the research evidence say about the long-term use of Titan?

The use of Titan for long-term treatment is documented in official evidence, specifically for maintenance therapy. Studies supporting this use, such as maintenance for duodenal ulcers and erosive esophagitis, have been carried out for periods up to one year and 48 weeks, respectively.


Q: Is Titan used to treat anything other than its main approved condition?

The official product information addresses only the specific approved indications listed in the labeling. Any other use is not detailed in the authorized product information.


Q: Can I drive or operate machinery while taking Titan?

The drug's effect on the ability to drive or operate machinery is not commonly reported in official documents. However, rare Central Nervous System (CNS) effects, such as dizziness and mental confusion, have been noted. Regulatory documents suggest observing potential impact due to noted CNS effects.


Q: What kind of monitoring (like blood tests) is generally recommended while taking Titan?

Monitoring of certain blood markers is often associated with this treatment. This is because official documents note the possibility of transient changes in liver function tests and rare blood count changes. Adjustments may also be needed for patients with reduced kidney function.


Q: Is Titan a controlled substance?

No, according to official drug classifications, Titan is not designated as a controlled substance by regulatory bodies like the U.S. Drug Enforcement Administration (DEA). It is an H2-receptor antagonist.


Q: How long does Titan stay in your system after the last dose?

Official information on pharmacokinetics indicates that the drug has an elimination half-life typically between 2.5 and 3 hours. This means that most of the drug is generally eliminated from the body within approximately 12.5 to 15 hours after the last dose.


Q: Why do some people experience trouble sleeping with Titan?

Trouble sleeping, or insomnia, is listed in official regulatory documents as a rare adverse reaction affecting the Central Nervous System. This effect may occur, though it is not classified as common.


Q: Are there known interactions between Titan and alcohol?

Clinical data reported in the drug's regulatory background suggests that Titan generally does not cause a clinically significant interaction with the consumption of alcohol.


Q: What is the typical age range of people who are prescribed Titan?

Safety and effectiveness have been established across a wide age range for certain approved conditions. Official documents indicate that the drug is used in patients as young as 1 month to 16 years of age, as well as in the adult and older adult populations.


Q: Is it true that Titan has a Black Box Warning?

No, official prescribing information provided by the FDA does not list a Black Box Warning for this drug.


Q: Can Titan be used by people with a history of heart problems?

Official documents list cardiac arrhythmias (irregular heartbeat) as a rare serious adverse reaction. Eligibility for use in individuals with a pre-existing history of heart problems is a determination made by a healthcare professional.


Q: Has Titan been studied in children?

Yes, official regulatory documents confirm that the safety and effectiveness of Titan have been established for the treatment of certain approved indications in pediatric patients aged 1 month to 16 years.


Q: What is the purpose of the different strengths (milligrams) that Titan comes in?

The drug is manufactured in different strengths (e.g., 75 mg, 150 mg, 300 mg) to serve various purposes. Lower strengths are typically used for Over-The-Counter (OTC) relief of heartburn, while higher prescription strengths are used for treating and maintaining chronic conditions like ulcers and GERD.


Q: What if I'm taking other prescription medications with Titan?

Official information states that Titan may interact with other medications, particularly those whose absorption is dependent on the level of stomach acid (gastric pH). The review of all co-administered medications by a healthcare provider is noted in regulatory precautions.


Q: What happens if I take too much Titan by accident?

Regulatory information states that accidental overdose necessitates seeking immediate medical help or contacting a Poison Control Center. Specific management guidance is available to healthcare professionals.


Q: What does the patient leaflet say about missed doses?

Patient leaflets typically provide specific instructions regarding missed doses, directing individuals on whether to take the dose when remembered or skip it if the next dose is near. It is important to always refer to the specific patient information provided with the medication.


Q: What is the official classification of the drug Titan?

Official documents classify the drug as a Histamine H2-receptor antagonist. This classification describes its mechanism, which involves blocking histamine receptors on the stomach lining cells to reduce acid production.


Q: Why is Titan only available by prescription?

Titan is actually available in both prescription (Rx) and Over-The-Counter (OTC) strengths. The higher Rx strengths are used to treat chronic, serious conditions like ulcers that require physician supervision, while lower strengths are available OTC for temporary relief of heartburn.


Q: What information is available about discontinuing Titan?

For acute conditions, treatment is prescribed for a limited duration (e.g., 4 to 8 weeks). Regulatory documents do not typically detail a tapering process, suggesting that abrupt discontinuation is not typically a concern following a prescribed short-term course.


Q: Are there different formulations of Titan (e.g., tablet vs. capsule)?

Yes, official documentation of dosage forms and strengths indicates that Titan is available in multiple formulations. These commonly include oral tablets, an oral solution (syrup), and an injection form.


Q: How should I store Titan?

Official information advises that the tablets should generally be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product should also be protected from excessive heat and humidity.


Q: Is Titan a drug that needs to be taken at the exact same time every day?

While regulatory labels do not mandate taking the drug at an exact time, specific dosing regimens are often recommended. For ulcer maintenance therapy, for example, it is typically prescribed once daily at bedtime, suggesting that a consistent administration time is often used in official dosing regimens.


Q: How does Titan impact fertility?

Based on animal reproduction studies cited in regulatory materials, there is no evidence of impaired fertility related to the drug’s use. Furthermore, it is reported to have no antiandrogenic action and no effect on sperm characteristics.

How should Titan be stored and disposed of?

The storage and disposal of Titan (Ranitidine HCl) are subject to official regulatory requirements, which include mandatory actions due to stability concerns.

Official Storage Conditions

Oral forms must be stored in the original container, tightly closed, away from excess heat, moisture, and light [2.4], [3.3]. The product should be stored below 30 C, as higher temperatures may increase impurity levels [1.5], [3.3]. All forms must be stored out of the sight and reach of children [2.4].

Stability Constraint Requirement
Temperature Risk Impurity levels increase significantly when stored at higher than room temperatures [1.5].
In-Use Stability For specific reformulated oral products, discard unused tablets 3 months (90 days) after first opening [1.1].

Mandatory Disposal Instructions

Regulatory agencies requested the withdrawal of all Ranitidine products due to the stability risk [1.5], [3.2]. Consumers must stop taking the medicine and dispose of it properly [1.5]. Disposal should follow the FDA's recommended home method: mix the medicine with an unappealing substance (like dirt or coffee grounds), place in a sealed plastic bag, and throw away in the household trash. The product should not be taken to a drug take-back location [1.5], [3.3].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Titan found in:

A-Z Index: